脂蛋白a在心血管疾病中的研究进展
Research Progress of Lipoprotein a in Cardiovascular Diseases
DOI: 10.12677/ACM.2023.1392070, PDF,    国家社会科学基金支持
作者: 阿依谢姆·库尔班*, 刘志强#：新疆医科大学第一附属医院，心脏中心，新疆 乌鲁木齐
关键词: 脂蛋白a；心血管疾病；进展；Lipoprotein a； Cardiovascular Diseases； Progress
摘要: 脂蛋白a [Lp(a)]是由含载脂蛋白APOB-100的低密度脂蛋白胆固醇样颗粒和载脂蛋白a组成的一种循环脂蛋白。Lp(a)通过促动脉粥样硬化、促炎症及促血栓形成等机制参与心血管疾病(CVD)发生、发展的病理生理过程，并独立于低密度脂蛋白胆固醇增加CVD风险，是CVD遗传、独立、因果因素。近年来，Lp(a)作为重要残余心血管风险备受关注，有望成为CVD降脂治疗新靶点。本文对Lp(a)概述、致病机制、Lp(a)与冠心病、钙化性主动脉瓣狭窄等疾病相关性及降脂治疗等方面的最新进展进行综述。
Abstract: Lipoprotein a [Lp(a)] is a circulating lipoprotein composed of low-density lipoprotein cholester-ol-like particles containing APO B-100 and APO a. Lp(a) is involved in the pathophysiological pro-cess of the occurrence and development of cardiovascular disease (CVD) through pro-atherosclerosis, pro-inflammation, pro-thrombosis and other mechanisms, and increases the risk of CVD independently of low-density lipoprotein cholesterol, which is a genetic, independent and causal factor of CVD. In recent years, Lp(a) has attracted much attention as an important resid-ual cardiovascular risk and is expected to become a new target for lipid-lowering therapy of CVD. In this paper, the overview of Lp(a), the pathogenesis, the correlation between Lp(a) and coronary heart disease, calcified aortic stenosis and other diseases, and the latest progress of lipid-lowering therapy were reviewed.
文章引用：阿依谢姆·库尔班, 刘志强. 脂蛋白a在心血管疾病中的研究进展[J]. 临床医学进展, 2023, 13(9): 14796-14802. https://doi.org/10.12677/ACM.2023.1392070

参考文献

[1] Roth, G.A., Mensah, G.A., Johnson, C.O., et al. (2020) Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update from the GBD 2019 Study. Journal of the American College of Cardiology, 76, 2982-3021. [Google Scholar] [CrossRef] [PubMed]
[2] 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2021概要[J]. 心脑血管病防治, 2022, 22(4): 20-36+40.
[3] 北京心脏学会. 脂蛋白(a)与心血管疾病风险关系及临床管理的专家科学建议[J]. 中国循环杂志, 2021, 36(12): 1158-1167.
[4] Tsimikas, S., Fazio, S., Ferdinand, K.C., et al. (2018) NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascu-lar Disease and Aortic Stenosis. Journal of the American College of Cardiology, 71, 177-192. [Google Scholar] [CrossRef] [PubMed]
[5] Orsó, E. and Schmitz, G. (2017) Lipoprotein(a) and Its Role in In-flammation, Atherosclerosis and Malignancies. Clinical Research in Cardiology Supplements, 12, 31-37. [Google Scholar] [CrossRef] [PubMed]
[6] Kronenberg, F., Mora, S., Stroes, E.S.G., et al. (2022) Lipopro-tein(a) in Atherosclerotic Cardiovascular Disease and Aortic Stenosis: A European Atherosclerosis Society Consensus Statement. European Heart Journal, 43, 3925-3946.
[7] 石惠薇, 热娜提•肉孜, 刘硕霖, 吴娜琼. 高脂蛋白a血症的相关治疗进展[J]. 心血管病学进展, 2021, 42(4): 297-301.
[8] 林振南, 贾砚慧, 陈恕凤. 脂蛋白(a)基因多态性与冠心病相关性的Meta分析[J]. 中国动脉硬化杂志, 2022, 30(2): 152-160.
[9] Wilson, D.P., Jacobson, T.A., Jones, P.H., et al. (2022) Use of Lipoprotein(a) in Clinical Practice: A Biomarker Whose Time Has Come. A Scientific Statement from the National Lipid Association. Journal of Clinical Lipidology, 13, 374-392. [Google Scholar] [CrossRef] [PubMed]
[10] Liu, T., Yoon, W.-S. and Lee, S.-R. (2021) Recent Updates of Lip-oprotein(a) and Cardiovascular Disease. Chonnam Medical Journal, 57, 36-43. [Google Scholar] [CrossRef] [PubMed]
[11] Tsimikas, S. (2017) A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. Journal of the American College of Cardiology, 69, 692-711. [Google Scholar] [CrossRef] [PubMed]
[12] Enas, E.A., Varkey, B., Dharmarajan, T.S., Pare, G. and Bahl, V.K. (2019) Lipoprotein(a): AN Independent, Genetic, and Causal Factor for Cardiovascular Disease and Acute Myocardial Infarction. Indian Heart Journal, 71, 99-112. [Google Scholar] [CrossRef] [PubMed]
[13] Niccoli, G., Cin, D., Scalone, G., et al. (2016) Lipoprotein(a) Is Re-lated to Coronary Atherosclerotic Burden and a Vulnerable Plaque Phenotype in Angiographically Obstructive Coronary Artery Disease. Atherosclerosis, 246, 214-220. [Google Scholar] [CrossRef] [PubMed]
[14] Niccoli, G., Chin, D., Scalone, G., et al. (2016) Data on the Lipoprotein(a), Coronary Atherosclerotic Burden and Vulnerable Plaque Phenotype in Angiographic Obstructive Coronary Artery Disease. Data in Brief, 7, 1409-1412. [Google Scholar] [CrossRef] [PubMed]
[15] Kaiser, Y., Daghem, M., Tzolos, E., et al. (2022) Association of Lipoprotein(a) with Atherosclerotic Plaque Progression. Journal of the American College of Cardiology, 79, 223-233. [Google Scholar] [CrossRef] [PubMed]
[16] Sumarjaya, I., Nadha, I.K.B. and Lestari, A.A.W. (2020) High Lipoprotein(a) Levels as a Predictor of Major Adverse Cardiovascular Events in Hospitalized-Acute Myocardial Infarc-tion Patients. Vascular Health and Risk Management, 16, 125-132. [Google Scholar] [CrossRef] 
[17] Hoursalas, A., Tsarouhas, K., Tsitsimpikou, C., et al. (2022) Mod-erately Elevated Lipoprotein(a) Levels Are Associated with an Earlier Need for Percutaneous Coronary Intervention in Recurrent Cardiovascular Disease. Experimental and Therapeutic Medicine, 24, Article No. 444. [Google Scholar] [CrossRef] [PubMed]
[18] Xue, Y., Jian, S., Zhou, W., et al. (2021) Associations of Lipopro-tein(a) with Coronary Atherosclerotic Burden and All-Cause Mortality in Patients with ST-Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention. Frontiers in Cardiovascular Medicine, 8, Article 638679. [Google Scholar] [CrossRef] [PubMed]
[19] Rallidis, L.S., Pavlakis, G., Foscolou, A., et al. (2018) High Levels of Lipoprotein(a) and Premature Acute Coronary Syndrome. Atherosclerosis, 269, 29-34. [Google Scholar] [CrossRef] [PubMed]
[20] Chen, Z., Jiang, C., Qu, H., et al. (2019) Association of Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients with Percutaneous Coronary Intervention. Archives of Medical Science, 15, 1375-1380. [Google Scholar] [CrossRef] [PubMed]
[21] 李新健, 徐昕晔, 王贵松. 血流储备分数用于指导急性ST段抬高型心肌梗死患者非梗死相关血管血运重建的研究进展[J]. 中国介入心脏病学杂志, 2022, 30(5): 378-381.
[22] 赵振燕, 宋光远, 吴永健. 脂蛋白(a)与钙化性主动脉瓣狭窄的关系[J]. 中国循环杂志, 2021, 36(9): 920-923.
[23] Zheng, K.H., Arsenault, B.J., Kaiser, Y., et al. (2019) ApoB/apoA-I Ratio and Lp(a) Associations with Aortic Valve Stenosis Incidence: Insights From the EPIC-Norfolk Prospective Population Study. Journal of the Ameri-can Heart Association, 8, e013020. [Google Scholar] [CrossRef] 
[24] Liu, Q., Yu, Y., Xi, R., et al. (2022) Association between Lipoprotein(a) and Calcific Aortic Valve Disease: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 9, Article 877140. [Google Scholar] [CrossRef] [PubMed]
[25] Liu, S.L., Rozi, R., Shi, H.-W., et al. (2020) Association of Serum Lipoprotein(a) Level with the Severity and Prognosis of Calcific Aortic Valve Stenosis: A Chinese Cohort Study. Jour-nal of Geriatric Cardiology, 17, 133-140.
[26] Jang, A.Y., Han, S.H., Sohn, I.S., Oh, P.C. and Koh, K.K. (2020) Lip-oprotein(a) and Cardiovascular Diseases—Revisited. Circulation Journal, 84, 867-874. [Google Scholar] [CrossRef] 
[27] Tsimikas, S., Gordts, P., Nora, C., Yeang, C. and Witztum, J.L. (2020) Statin Therapy Increases Lipoprotein(a) Levels. European Heart Journal, 41, 2275-2284. [Google Scholar] [CrossRef] [PubMed]
[28] Lincoff, A.M., Nicholls, S.J., Riesmeyer, J.S., et al. (2017) Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. New England Journal of Medicine, 376, 1933-1942. [Google Scholar] [CrossRef] 
[29] Farmakis, I., Doundoulakis, I., Pagiantza, A., et al. (2021) Lipoprotein(a) Reduction with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis. Journal of Cardiovascular Pharmacology, 77, 397-407. [Google Scholar] [CrossRef] 
[30] Mach, F., Baigent, C., Catapano, A.L., et al. (2020) 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. Euro-pean Heart Journal, 41, 111-188. [Google Scholar] [CrossRef] [PubMed]
[31] Warden, B.A. and Duell, P.B. (2021) Inclisiran: A Novel Agent for Lowering Apolipoprotein B-Containing Lipoproteins. Journal of Cardiovascular Pharmacology, 78, e157-e174. [Google Scholar] [CrossRef] 
[32] 杨冬梅, 潘彦, 白文伟. 载脂蛋白B合成抑制剂治疗血脂异常的有效性与安全性的Meta分析[J]. 心肺血管病杂志, 2017, 36(10): 858-863.
[33] Swerdlow, D.I., Rider, D.A., Yavari, A., et al. (2022) Treatment and Prevention of Lipoprotein(a)-Mediated Cardiovascular Disease: The Emerging Potential of RNA Interference Therapeutics. Cardiovascular Research, 118, 1218-1231. [Google Scholar] [CrossRef] [PubMed]
[34] 赵量, 高莹, 刘庚, 等. 血脂净化治疗家族性高胆固醇血症的单中心研究[J]. 中华心血管病杂志, 2022, 50(6): 585-590.

为你推荐